Serum levels of TWEAK in patients with psoriasis vulgaris

Basit Öğe Kaydı
dc.contributor.authorBilgic, Ozlem
dc.contributor.authorSivrikaya, Abdullah
dc.contributor.authorToker, Aysun
dc.contributor.authorUnlu, Ali
dc.contributor.authorAltinyazar, Cevdet
dc.date.accessioned2024-02-23T14:02:41Z
dc.date.available2024-02-23T14:02:41Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractTumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) has been implicated in the pathogenesis of a variety of inflammatory disorders and autoimmune diseases. However, studies conducted on the relationship of TWEAK and psoriasis patients are limited. In this study, we aimed to explore the serum levels of TWEAK and investigated whether TWEAK levels are associated with clinical variables and expression of other well-known psoriasis-related cytokines including IL-6, IL-23 and TNF-alpha. Fortyfive patients with chronic plaque psoriasis and 43 controls were enrolled in this study. The severity of psoriasis was assessed by the Psoriasis Area and Severity Index (PASI). Serum levels of cytokines were measured using commercial enzyme-linked immunosorbent assay (ELISA) kits. The mean TWEAK, IL-6, IL-23, and TN-alpha levels were significantly higher in psoriasis patients than in control subjects. However, there were no significant correlations between the psoriasis severity, the illness duration and serum cytokine levels. This study shows that TWEAK may be associated with the pathogenesis of psoriasis, like TNF-alpha, IL-6, and IL-23. (C) 2015 Elsevier Ltd. All rights reserved.en_US
dc.description.sponsorshipScientific Research Project Coordination Unit of Selcuk University [13401129]en_US
dc.description.sponsorshipFunding for this study was provided by a grant from the Scientific Research Project Coordination Unit of Selcuk University (Project no: 13401129).en_US
dc.identifier.doi10.1016/j.cyto.2015.10.004
dc.identifier.endpage13en_US
dc.identifier.issn1043-4666
dc.identifier.issn1096-0023
dc.identifier.pmid26499979en_US
dc.identifier.scopus2-s2.0-84944931161en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage10en_US
dc.identifier.urihttps://doi.org/10.1016/j.cyto.2015.10.004
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11812
dc.identifier.volume77en_US
dc.identifier.wosWOS:000366540500002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Ltd- Elsevier Science Ltden_US
dc.relation.ispartofCytokineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTumor Necrosis Factor-Related Weak Induceren_US
dc.subjectOf Apoptosisen_US
dc.subjectTumor Necrosis Factor-Alphaen_US
dc.subjectInterleukin-6en_US
dc.subjectInterleukin-23en_US
dc.subjectPsoriasisen_US
dc.titleSerum levels of TWEAK in patients with psoriasis vulgarisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu